Hengrui Medicine
Hengrui Medicine is a Chinese pharmaceutical company focused on innovative medicines, particularly oncology, immunology, anesthesia, contrast media, and other hospital specialties.
Last updated October 22, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Hengrui Medicine, formally Jiangsu Hengrui Pharmaceuticals Co., Ltd., is a China-based pharmaceutical company headquartered in Lianyungang, Jiangsu. The business developed from a regional pharmaceutical manufacturer into one of China’s best-known domestic drug companies, with activities spanning research, clinical development, manufacturing, commercialization, and international licensing. It is especially associated with oncology medicines, but its portfolio also covers anesthetics, contrast agents, autoimmune and inflammatory diseases, metabolic disorders, cardiovascular treatment, and other hospital-oriented therapeutic areas. The company’s historical development reflects the shift in China’s pharmaceutical industry from a manufacturing model centered on generic and injectable medicines toward one emphasizing proprietary research and development. Hengrui built a large domestic commercial organization while investing in laboratories, clinical programs, manufacturing capacity, and regulatory capabilities. Its strategy has combined internally discovered candidates, reformulated or improved medicines, generic products, and partnerships with multinational pharmaceutical companies. This mix allowed the company to establish revenue and market access while gradually increasing the proportion of innovative products in its pipeline. Hengrui became publicly traded on the Shanghai Stock Exchange in 2000. During the 2000s and 2010s, it expanded its presence in major Chinese hospitals and developed a reputation for active investment in research. Oncology became its most visible growth area. Products and development programs associated with the brand have included the immune checkpoint inhibitor camrelizumab, the targeted cancer medicine apatinib, several chemotherapy products, and supportive or perioperative medicines. The company has also pursued combination regimens, seeking to use its oncology portfolio across multiple tumor types and treatment settings. A major strategic transition occurred as China’s centralized and volume-based procurement policies increased pressure on prices for mature generic medicines. Hengrui responded by emphasizing innovative drugs, research-based launches, international development, and selective licensing transactions. It has entered collaborations and licensing arrangements involving investigational and marketed assets, including transactions with companies outside China. These deals have helped extend the potential reach of its pipeline while providing external validation for selected candidates. Hengrui’s international ambitions include clinical trials conducted under international standards, regulatory submissions outside mainland China, and partnerships for overseas commercialization. Its international business remains smaller than its China business, but the company has sought to position itself as a research-driven Chinese pharmaceutical enterprise rather than solely a domestic generics supplier. The brand operates in a highly regulated and competitive environment. Its performance is influenced by Chinese reimbursement and procurement policy, regulatory review, hospital purchasing, patent and exclusivity conditions, clinical-trial outcomes, and the ability to convert research spending into commercially successful products. Hengrui remains an active public company and one of the prominent Chinese pharmaceutical firms by research scale and domestic market presence. The exact composition of its marketed portfolio and executive team changes over time as products receive approvals, lose exclusivity, or are transferred through licensing arrangements.
History
Hengrui Medicine traces its origins to a pharmaceutical manufacturing business established in Lianyungang, Jiangsu, in 1970. The enterprise initially operated within the product and distribution environment of China’s state-influenced pharmaceutical industry. Over time, it developed manufacturing capabilities in medicines used by hospitals and expanded its commercial presence in China. Its later corporate identity became associated with Jiangsu Hengrui Pharmaceuticals Co., Ltd. The company’s growth accelerated as China’s healthcare market expanded and hospitals demanded dependable supplies of injectable drugs, anesthetics, oncology products, contrast agents, and other prescription medicines. Hengrui used this base to build production facilities, a nationwide sales organization, and a portfolio that combined established medicines with products requiring more specialized manufacturing. It listed on the Shanghai Stock Exchange in 2000, providing a platform for expansion and increasing public visibility. During the 2000s, Hengrui began moving more decisively toward research-based pharmaceuticals. It invested in laboratories, scientists, clinical trials, and regulatory capabilities, while continuing to operate across generic and hospital-medicine categories. Oncology became the company’s principal research focus. The strategy included both conventional cytotoxic medicines and newer targeted or immune-based approaches. Apatinib became an important targeted oncology product, while the development of camrelizumab marked the company’s entry into the increasingly important immune checkpoint inhibitor segment. The approval and commercialization of camrelizumab in China represented a significant step in Hengrui’s transformation into an innovative-drug company. The medicine was developed across several cancer indications and was studied in combination with other therapies. Hengrui also continued developing anesthetics, contrast media, perioperative medicines, and other products that supported its established hospital presence. This portfolio structure gave the company a combination of recurring commercial products and higher-risk, higher-value research programs. China’s pharmaceutical-policy reforms created both opportunities and pressure. Centralized procurement and reimbursement reforms reduced prices for many mature medicines and increased competition based on cost, quality, and supply reliability. Hengrui therefore emphasized proprietary products, improved formulations, clinical differentiation, patent and regulatory capabilities, and international collaboration. The company continued to retain a generic and hospital-products base, but its stated strategic direction increasingly centered on innovation. Hengrui has pursued overseas development through international clinical programs, regulatory work, and licensing or collaboration transactions. These arrangements have allowed external partners to participate in the development or commercialization of selected assets, while Hengrui has sought to gain experience in global drug development and access to foreign markets. Its international footprint is still not equivalent to that of the largest multinational pharmaceutical companies, and the majority of its commercial importance remains connected to China. The company’s current identity is that of a large, publicly traded Chinese pharmaceutical enterprise with substantial domestic commercialization capabilities and a growing innovative-medicine pipeline. Its principal challenges include the cost and uncertainty of clinical research, regulatory competition, pricing reform, patent disputes, competition from domestic and multinational drugmakers, and the need to turn promising candidates into durable global products. Hengrui continues to operate under the Hengrui brand while developing medicines across oncology and other specialty areas.
- 2021
Greater emphasis on innovation amid procurement reform
[1]The company increased its strategic focus on innovative drugs as centralized procurement placed additional price pressure on mature products.
- 2020
Broader immuno-oncology development
[1]Hengrui continued expanding clinical development of camrelizumab and combination approaches across additional tumor types.
- 2019
Camrelizumab approved in China
[3]Camrelizumab received its first Chinese approval and became a central product in Hengrui’s immuno-oncology strategy.
- 2014
Apatinib approved in China
[3]Apatinib, a targeted oncology medicine, received approval in China and became an important product in Hengrui’s cancer portfolio.
- 2010
Research-led expansion
[1]The company accelerated investment in proprietary drug discovery, clinical development, and research infrastructure.
- 2000
Shanghai Stock Exchange listing
[2]Jiangsu Hengrui Pharmaceuticals became publicly listed on the Shanghai Stock Exchange under ticker 600276.
- 1970
Pharmaceutical business established in Lianyungang
[1]The enterprise that developed into Hengrui Medicine was established in Lianyungang, Jiangsu.
Products and positioning
A research-oriented Chinese pharmaceutical company transitioning from a broad hospital-medicine and generic-drug base toward proprietary innovative medicines and international commercialization.
Immune checkpoint inhibitor · 2019
Camrelizumab
Camrelizumab is a monoclonal antibody targeting PD-1. It is one of Hengrui’s best-known innovative medicines and has been developed and approved in China for multiple oncology indications. The company has studied it both as a monotherapy and in combination with chemotherapy, targeted medicines, or other treatment approaches. Its development illustrates Hengrui’s transition from a predominantly hospital-generic portfolio toward proprietary immuno-oncology products.
Targeted oncology medicine · 2014
Apatinib
Apatinib is a small-molecule anti-angiogenic medicine designed to inhibit signaling associated with tumor blood-vessel formation. It became an important Hengrui oncology product after approval in China and has been used in the treatment of selected advanced cancers. The product helped establish Hengrui’s commercial and clinical presence in targeted cancer therapy before the company’s later expansion in immune checkpoint medicines.
Hospital medicines
Anesthetics and perioperative medicines
Hengrui has long maintained a substantial portfolio of anesthetics, sedatives, analgesics, and other medicines used around surgery and hospital procedures. These products support the company’s established hospital sales network and manufacturing base. The category includes both mature products and formulations requiring specialized injectable production, although individual products and commercial status vary by market and procurement cycle.
Diagnostic imaging medicines
Contrast media
Contrast-media products are used to improve the visibility of organs, blood vessels, and tissues during diagnostic imaging procedures. Hengrui has operated in this hospital-focused category alongside oncology and anesthesia. The business benefits from manufacturing and distribution capabilities serving medical institutions, while its products are subject to procurement, safety, quality, and regulatory requirements.
Oncology medicines
Chemotherapy medicines
Hengrui manufactures and markets a range of conventional oncology medicines, including injectable and other hospital-administered therapies. These products formed an important foundation for its oncology franchise and commercial relationships with Chinese hospitals. They also provide clinical and market infrastructure supporting the company’s newer targeted and immune-based cancer products, although mature products face generic competition and centralized procurement price pressure.
Controversies
2020
Sales staff involvement in doctor bribery case raises concerns over pharmaceutical promotion compliance
In May 2020, Securities Times reported that a judgment in a doctor bribery case involved cash transactions between sales staff of a Hengrui Medicine subsidiary and hospital personnel. Hengrui responded that it was the personal conduct of subsidiary employees, the relevant personnel had left, and responsible leaders were reassigned. The incident sparked discussion on pharmaceutical promotion compliance and does not determine that all academic promotion expenses constitute bribery.
2020
Hengrui responds to media questions about subsidiary employee bribery case and sales expenses
Hengrui Pharmaceutical said a subsidiary employee's conduct in a bribery case involving a doctor at a Zhejiang hospital seriously violated company rules and exposed management gaps. It said the relevant personnel had left and the subsidiary's responsible leader had been transferred from the post, and said it would strengthen compliance management of subsidiaries. The company also responded to media questions about sales expenses.
Brand decisions
2022
Use of licensing and external partnershipsM&ABackground
Hengrui sought to broaden the reach of selected pipeline and marketed assets while gaining access to international development and commercialization capabilities.
Action taken
The company continued to pursue licensing and collaboration arrangements with external pharmaceutical partners for selected products and development programs.
Aftermath
These transactions supported Hengrui’s internationalization strategy and provided potential overseas routes for its medicines, although the commercial outcome differs by asset and partner.
2021
Shift toward innovative medicinesStrategyBackground
China’s centralized procurement and reimbursement reforms increased price and volume pressure on established generic and injectable medicines. At the same time, oncology and other specialty therapies offered opportunities for differentiated growth.
Action taken
Hengrui emphasized research and development, proprietary drug candidates, clinical differentiation, international development, and selective licensing while retaining a broad hospital-medicine base.
Aftermath
The strategy reinforced the company’s identity as an innovative Chinese pharmaceutical enterprise, but it also exposed the business to high research costs, clinical uncertainty, regulatory risk, and competition in crowded oncology markets.
Recent events
- Unconfirmed
Hengrui Pharma and Shifangyun sign strategic cooperation agreement[10]
Hengrui Pharma and Shifangyun signed a strategic cooperation agreement to build an AI-agent ecosystem for pharmaceuticals. Shifangyun will provide AI technology and data-governance capabilities, while Hengrui will provide pharmaceutical research and development, clinical research, and manufacturing resources.
- Unconfirmed
Novo Nordisk to pay up to $2.6 billion to Hengrui for rights to weight-loss pill[11]
Reported:
Reuters reported that Novo Nordisk is to pay up to $2.6 billion to China's Hengrui Pharma for rights to a weight-loss pill.
Hengrui announces investment and YY-20394 rights agreement with Yingli Pharma[12]
Reported:
Hengrui Pharma announced a proposed $20 million investment in Yingli Pharma and an agreement granting Hengrui joint development rights and exclusive commercialization rights for YY-20394 in Greater China.
Hengrui responds to media questions about subsidiary employee bribery case and sales expenses[9]
Reported:
Hengrui Pharmaceutical said a subsidiary employee’s conduct in a bribery case involving a doctor at a Zhejiang hospital seriously violated company rules and exposed management gaps. It said the relevant personnel had left and the subsidiary’s responsible leader had been transferred from the post, and said it would strengthen compliance management of subsidiaries. The company also responded to media questions about sales expenses.
Hengrui Medicine releases 2019 annual results[13]
Hengrui Medicine released its 2019 results on March 22, reporting revenue of 23.289 billion yuan and net profit attributable to shareholders of 5.328 billion yuan.
Sources16 sources
- 1Hengrui Medicine official websitehengrui.com
- 2Shanghai Stock Exchangesse.com.cn
- 3National Medical Products Administration of Chinanmpa.gov.cn
- 4Jiangsu Hengrui Pharmaceuticals reference pageen.wikipedia.org
- 5恒瑞医药 - 关于恒瑞hengrui.com
- 6恒瑞医药 - 社会公益hengrui.com
- 7Jiangsu Hengrui - Wikipediaen.wikipedia.org
- 8Sales staff involvement in doctor bribery case raises concerns over pharmaceutical promotion compliancenews.stcn.com
- 9Hengrui responds to media questions about subsidiary employee bribery case and sales expensesfinance.sina.com.cn
- 10恒瑞医药与十方云签署战略合作协议finance.eastmoney.com
- 11诺和诺德将向恒瑞支付至多26亿美元获得减肥药权益news.google.com
- 12恒瑞医药宣布入股璎黎药业并获得YY-20394相关权益finance.sina.com.cn
- 13恒瑞医药发布2019年业绩报告finance.sina.com.cn
- 14【市场】恒瑞医药半年报公布：营收及净利增速下滑finance.sina.com.cn
- 15创新药进入收获期 恒瑞医药一季度净利同比增一成finance.sina.com.cn
- 16恒瑞医药(600276):回应媒体质疑 销售费用率处于行业居中水平finance.sina.com.cn
Cite this profile: Cite the canonical profile. /brand-wiki/恒瑞医药 · Editorial policy · How profiles are compiled